⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL745572 | 0.75 | — | — | |
| SCHEMBL988803 | 0.74 | CYP2A6 (0.53) | — | |
| SCHEMBL1316597 | 0.74 | RAB9A (0.48) | — | |
| SCHEMBL988802 | 0.73 | ATM (0.41) | — | |
| SCHEMBL16834083 | 0.73 | HPGDS (0.40) | — | |
| SCHEMBL16834634 | 0.73 | — | — | |
| SCHEMBL18662841 | 0.72 | CYP2A6 (0.44) | — | |
| SCHEMBL16834136 | 0.72 | MEN1 (0.44) | — | |
| SCHEMBL1201737 | 0.71 | LMNA (0.42) | — | |
| SCHEMBL16834686 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219452-B1 | NOVEL 3,5-DISUBSTITUTED PYRIDINE AND 3,5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME | MITSUBISHI TANABE PHARMA CORP (JP) | 2025-01-01 | — | — | EP | claimed |
| EP-3831812-B1 | NOVEL 3, 5-DISUBSTITUTED PYRIDINE AND 3, 5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME | MITSUBISHI TANABE PHARMA CORP (JP) | 2023-05-10 | — | — | EP | claimed |
| WO-2011008788-A1 | FLUORO-SUBSTITUTED COMPOUNDS AS KINASE INHIBITORS AND METHODS OF USE THEREOF | ZHANG DAWEI (US) | 2011-01-20 | — | — | WO | claimed |
| US-20170088520-A1 | DEUBIQUITINASE INHIBITORS | PHARMAKEA, INC. | 2017-03-30 | — | — | US | disclosed |
| WO-2011008788-A1 | FLUORO-SUBSTITUTED COMPOUNDS AS KINASE INHIBITORS AND METHODS OF USE THEREOF | ZHANG DAWEI (US) | 2011-01-20 | — | — | WO | disclosed |